Medtech veteran Keltjens to head Sapiens Steering Brain Stimulation
This article was originally published in Clinica
Executive Summary
Dutch firm Sapiens Steering Brain Stimulation, which is developing technology to make deep brain stimulation (DBS) more precise, has appointed medical device stalwart Jan Keltjens president and CEO. Mr Keltjens has over 30 years of experience, most recently heading up Swiss force-sensing catheter ablation specialist Endosense, which was acquired by St Jude Medical this year (www.clinica.co.uk, 19 August 2013). He has also been either CEO or chairman at various companies including CryoCath Technologies, bought by Medtronic in 2008 (www.clinica.co.uk, 29 September 2008), Surpass Medical, acquired by Stryker in 2012 (www.clinica.co.uk, 18 October 2012), and AngioDynamics – but left the latter in 2011 after poor financial results (www.clinica.co.uk, 14 June 2011). He has experience in the neuroscience field, as vice-president and later worldwide general manager of neurovascular at Johnson & Johnson’s Cordis subsidiary from 1995 to 2007. Philips spin-out Sapiens has previously been a hot pick in Clinica’s Medtech Ventures (www.clinica.co.uk, 16 August 2012).
You may also be interested in...
What are the hottest innovations from Israel?
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
EuroPCR: St Jude and Philips talk up rival intravascular imaging techs
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
EuroPCR: Medtronic's drug-coated balloon keeps rising
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.